Samuel Kintz - 25 Mar 2024 Form 4 Insider Report for Enliven Therapeutics, Inc. (ELVN)

Role
PRESIDENT AND CEO, Director
Signature
/s/ Ben Hohl, by power of attorney
Issuer symbol
ELVN
Transactions as of
25 Mar 2024
Net transactions value
-$197,221
Form type
4
Filing time
27 Mar 2024, 17:03:00 UTC
Previous filing
28 Feb 2024
Next filing
15 Apr 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ELVN Common Stock Options Exercise $13,440 +12,000 $1.12* 12,000 25 Mar 2024 Direct F1
transaction ELVN Common Stock Sale $125,820 -7,329 -61% $17.17 4,671 25 Mar 2024 Direct F1, F2
transaction ELVN Common Stock Sale $84,841 -4,671 -100% $18.16 0 25 Mar 2024 Direct F1, F3
holding ELVN Common Stock 1,087,525 25 Mar 2024 See footnote F4
holding ELVN Common Stock 88,531 25 Mar 2024 See footnote F5
holding ELVN Common Stock 88,531 25 Mar 2024 See footnote F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELVN Stock Option (right to buy) Options Exercise $0 -12,000 -4.4% $0.000000 260,550 25 Mar 2024 Common Stock 12,000 $1.12 Direct F1, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023.
F2 This transaction was executed in multiple trades at prices ranging from $16.90 to $17.59. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3 This transaction was executed in multiple trades at prices ranging from $17.96 to $18.80. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4 The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee.
F5 The shares are held of record by an irrevocable trust dated October 26, 2021 for the benefit of the Reporting Person's elder son and for which the Reporting Person serves as an investment advisor.
F6 The shares are held of record by an irrevocable trust dated October 26, 2021 for the benefit of the Reporting Person's younger son and for which the Reporting Person serves as an investment advisor.
F7 The option, originally for 344,550 shares, is subject to an early exercise provision and is immediately exercisable. Shares subject to the option vest in 48 equal monthly installments beginning on May 3, 2020.